North America Advanced Drug Delivery Systems Market Size
|Study Period||2018 - 2028|
|Base Year For Estimation||2022|
|Forecast Data Period||2023 - 2028|
|Historical Data Period||2018 - 2021|
*Disclaimer: Major Players sorted in no particular order
Need a report that reflects how COVID-19 has impacted this market and its growth?
North America Advanced Drug Delivery Systems Market Analysis
The North American drug delivery systems market is expected to register a CAGR of around 4.8% during the forecast period.
The COVID-19 pandemic had positively impacted the growth of the advanced drug delivery systems market. Numerous research highlights how advanced drug delivery systems (ADDS) aid in the development of improved therapeutic agent delivery systems (dosage forms). For instance, an article published in Elsevier in November 2021 observed that nanotechnology-based techniques were playing a key role in advancing the diagnosis and production of COVID-19 vaccines. In addition, advanced nanoscience has access to all the necessary tools such as theranostics, nucleic acid testing like reverse transcription polymerase chain reaction (rt-PCR), computed tomography, protein testing, etc., that are essential to incorporate such techniques into feasible strategies. Moreover, with the released restrictions and resumed company activities, the studied market is anticipated to grow over the forecast period.
Factors such as the development of new drugs and biologics, advancements in understanding human biology and diseases, as well as increased R&D spending are expected to boost the market growth over the forecast period.
Advancements in several biology-oriented initiatives have created a unique opportunity to better comprehend the molecular causes of human diseases and generate novel medications and biologics based on these factors. The recently discovered advanced drug delivery systems include lipid, protein, and polymer technologies with better lipid distribution in the body, which also reduce the rate of drug clearance and avoid drug degradation owing to the environment. Also, advanced drugs and biologics offer increased efficiency with a reduced dosage of pharmaceuticals which require an advanced drug delivery system for the targeted and controlled release of novel molecules in tissues and cells to optimize their potential benefits for patients. For instance, in December 2021, AstraZeneca scientists were working on a wide variety of nanoparticles with the goal of delivering new treatment modalities to previously inaccessible targets and precisely regulating their release in patient-friendly formulations. Thus, such innovation is expected to fuel the market growth.
In addition to medicines and biologics, drug-eluting implants have the potential to offer continuous treatment and lower drug dosages. Advanced sustained-release systems work to treat conditions, including intestinal infections. Self-injecting devices are becoming increasingly popular, and a significant class of medical devices has also lately arisen from the pipeline of biologics, biosimilars, and auto-injectors.
Furthermore, the growing research and development spending by the companies to increase the production of new drugs and biologics is anticipated to fuel market growth. For instance, in September 2022, Novartis invested USD 300 million to increase its production and development capabilities for biological drugs. In addition, the company invested USD 110 million in clinical manufacturing capacity in Slovenia and USD 60 million in development manufacturing capacity in Austria to further integrate biologics development within existing facilities. Also, in September 2022, CuraTeQ Biologics, a wholly-owned subsidiary of Aurobindo Pharma, invested approximately INR 300 crore in the capacity expansion of biologics manufacturing facilities. In addition, the company received approval for entering contract manufacturing operations (CMO) for biologicals.
Moreover, the companies are focusing on adopting various business strategies such as new product launches, partnerships, collaborations, and others which are also contributing to market growth. For instance, in February 2022, NuGen Medical Devices Inc. delivered a purchase order from a Taiwanese medical distributor Shin-Ya Biotechnology Co. Ltd, for its InsuJet needleless injection system. This is part of a multi-year sales and distribution contract with a minimum commitment of CDN 100,000 during the first two years.
Therefore, owing to the aforementioned factors, such as the increasing advancements in biological drugs, growing R&D spending, and increasing company activities, are anticipated to grow over the forecast period. However, the product recalls of advanced drug delivery and the challenges in nanomedicine-based drug delivery are likely to impede the growth of the advanced drug delivery systems market in North America over the forecast period.
North America Advanced Drug Delivery Systems Market Trends
The Oral Drug Delivery System Segment is Expected to Witness Significant Growth Over the Forecast Period
The oral drug delivery system is expected to witness significant growth in the advanced drug delivery systems market over the forecast period owing to the factors such as the growing burden of target diseases such as diabetes, cancer, and others, as well as the new product launches. In addition, several advantages are offered by oral drug delivery, such as dosage flexibility, non-invasiveness, patient compliance, the convenience of drug administration, and fast-acting, over other delivery systems, making it the most preferred route.
Additionally, pharmaceutical companies are paying more attention to the oral-release drug delivery systems as a result of rising costs and difficulties associated with developing, patenting, and marketing new drug entities, with simultaneous recognition of the therapeutic advantages of controlled drug delivery.
The increasing demand for controlled-release formulations and new product introductions in important therapeutic areas such as the central nervous system and cardiovascular, metabolic, and respiratory diseases have sped up the development of improved oral drug delivery systems. For instance, in October 2022, Biora Therapeutics participated in the 12th annual Partnership Opportunities in Drug Delivery Conference in Boston. The session explores the challenges related to the oral delivery of biologics, which is currently limited by barriers in the gastrointestinal tract to systemic absorption of drugs, and the innovations being developed to overcome these barriers for effective oral delivery, including novel ingestible capsules.
Moreover, the increasing company focus on adopting key strategies such as partnerships, agreements, and others increases the availability of advanced drug delivery systems. This is expected to propel the segment’s growth. For instance, in May 2022, Rapid Dose Therapeutics Corp. signed several agreements with Oakland Health Limited to support and accelerate the development and commercialization of the Company’s QuickStrip system, an oral thin-film delivery, for COVID-19 vaccines. Similarly, in January 2021, Janssen Research and Development, one of the Janssen Pharmaceutical Companies of Johnson and Johnson, in partnership with BioMed X, launched a research project to discover novel transport mechanisms in the human intestinal tract that could be used for oral delivery of diverse therapeutic modalities.
Therefore, owing to the factors such as the advantages offered by the oral drug delivery system over other delivery routes and increasing company activities and initiatives, the studied segment is anticipated to grow over the forecast period.
To understand key trends, Download Sample Report
The United States is Expected to Have the Significant Market Share Over the Forecast Period
The United States is expected to hold a significant share in the advanced drug delivery system market over the forecast period owing to the factors such as the better adoption of improved drug delivery solutions and follow-up of advanced treatment approaches in healthcare. In addition, the growing inclination toward self-administration of drugs, increasing innovations in injectable drug delivery systems, the high adoption rate of new healthcare technologies, and the high prevalence of chronic diseases are also expected to boost market growth over the forecast period.
The growing burden of target diseases such as cancer, neurological diseases, cardiovascular diseases, and others is expected to increase the demand for effective and advanced drug delivery systems. This is anticipated to fuel market growth. For instance, according to an article published in JAMA, in January 2022, about 17.1% of women and 5.6% of men reported having migraine symptoms in 2021 in the United States. Also, as per 2023 statistics published by ACS, about 1,958,310 new cancer cases are expected to be diagnosed among the population in the United States in 2023.
Furthermore, the joint initiatives taken by the market players, non-profit organizations, and government agencies are also propelling the growth of the market in the country. For instance, in March 2022, TFF Pharmaceuticals Inc. entered into a Cooperative Research and Development Agreement (CRADA) with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID). Under the agreement, TFF Pharmaceuticals and USAMRIID evaluate the immune response of a dry powder recombinant Vesicular Stomatitis Virus Severe Acute Respiratory Syndrome Coronavirus-2 Glycoprotein (TFFD-rVSV-SARS2-GP) vaccine formulated using TFF’s Thin Film Freezing technology. Such joint initiatives are also expected to propel the growth of the market.
Moreover, the rising company’s focus on adopting various strategic initiatives such as collaboration, partnerships, agreements, and others is expected to fuel the market growth in the region over the forecast period. For instance, in February 2022, Aquestive Therapeutics announced FDA clearance of an investigational new drug application (IND) for AQST-109 epinephrine oral film. Also, in December 2021, Wrinkles Schminkles launched self-dissolving microneedle patches, having 1,800 microneedles, that use innovative technology to directly deliver active ingredients deep into the skin. The patch smooths out tiny lines and wrinkles by self-dissolving and releasing the active ingredients into the dermal layers of the skin.
Therefore, owing to the aforementioned factors, such as the high burden of cancer and cardiovascular diseases and growing company activities, the studied market is anticipated to grow over the forecast period.
To understand geography trends, Download Sample Report
North America Advanced Drug Delivery Systems Industry Overview
The North American advanced drug delivery systems market is moderately competitive. Due to the continuous technological advancements in the drug delivery system, there are possibilities for newer players to enter the market over the coming years. Some of the key players in the market include 3M, Bayer, Pfizer Inc., Aradigm Corporation, Boston Scientific Corporation, and West Pharmaceutical Services Inc.
North America Advanced Drug Delivery Systems Market Leaders
Boston Scientific Corporation
West Pharmaceutical Services, Inc.
*Disclaimer: Major Players sorted in no particular order
North America Advanced Drug Delivery Systems Market News
- Jan 2023: The United States FDA approved Airsupra (albuterol and budesonide) inhalation aerosol for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of asthma attacks in patients with asthma 18 years of age and older.
- Mar 2022: The United States FDA approved the first generic of Symbicort (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol for the treatment of two common pulmonary health conditions: asthma in patients six years of age and older; and chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
North America Advanced Drug Delivery Systems Market Report - Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Development of New Drugs and Biologics
4.2.2 Advancements in Understanding Human Biology and Diseases
4.2.3 Increased R&D Spending
4.3 Market Restraints
4.3.1 Product Recalls of Advanced Drug Delivery Products
4.3.2 Challenges in Nanomedicine-based Drug Delivery
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD Million)
5.1.1 Oral Drug Delivery System
5.1.2 Injection-based Drug Delivery System
5.1.3 Inhalation/Pulmonary Drug Delivery System
5.1.4 Transdermal Drug Delivery System
5.1.5 Transmucosal Drug Delivery System
5.1.6 Carrier-based Drug Delivery System
5.1.7 Other Types
5.2.1 Cardiovascular Diseases
5.2.7 Inflammatory Diseases
5.2.9 Other Applications
5.3.2 Implants and Intrauterine Devices
5.3.3 Targeted Drug Delivery
5.3.4 Polymeric Drug Delivery
5.3.5 Other Technologies
5.4.1 United States
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.2 Aradigm Corporation
6.1.3 Amgen Inc
6.1.4 Astrazeneca PLC
6.1.5 Bayer Healthcare
6.1.6 Boston Scientific Corporation
6.1.7 Pfizer Inc
6.1.8 Merck & Co. Inc.
6.1.9 Novartis AG
6.1.10 West Pharmaceutical Services Inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
North America Advanced Drug Delivery Systems Market Research FAQs
What is the current North America Advanced Drug Delivery Systems Market size?
The North America Advanced Drug Delivery Systems Market is projected to register a CAGR of 4.8% during the forecast period (2023-2028).
Who are the key players in North America Advanced Drug Delivery Systems Market?
3M, Aradigm Corporation, Boston Scientific Corporation, West Pharmaceutical Services, Inc. and Pfizer Inc. are the major companies operating in the North America Advanced Drug Delivery Systems Market.
North America Advanced Drug Delivery Systems Industry Report
Statistics for the 2023 North America Advanced Drug Delivery Systems market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. North America Advanced Drug Delivery Systems analysis includes a market forecast outlook to for 2023 to 2028 and historical overview. Get a sample of this industry analysis as a free report PDF download.